146 related articles for article (PubMed ID: 2655094)
1. Optimal dosing with carboplatin.
Ozols RF
Semin Oncol; 1989 Apr; 16(2 Suppl 5):14-8. PubMed ID: 2655094
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
Mangioni C; Bolis G; Pecorelli S; Bragman K; Epis A; Favalli G; Gambino A; Landoni F; Presti M; Torri W
J Natl Cancer Inst; 1989 Oct; 81(19):1464-71. PubMed ID: 2674459
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin in the first-line chemotherapy of ovarian cancer.
Alberts DS; Canetta R; Mason-Liddil N
Semin Oncol; 1990 Feb; 17(1 Suppl 2):54-60. PubMed ID: 2406922
[TBL] [Abstract][Full Text] [Related]
4. Dose intensity of carboplatin in combination with cyclophosphamide or ifosfamide.
Green JA; Smith K
Cancer Chemother Pharmacol; 1990; 26 Suppl():S22-5. PubMed ID: 2189593
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin in the treatment of ovarian cancer.
Alberts DS; Mason-Liddil N
Semin Oncol; 1989 Apr; 16(2 Suppl 5):19-26. PubMed ID: 2655095
[TBL] [Abstract][Full Text] [Related]
7. High dose cisplatin and high dose carboplatin in refractory ovarian cancer.
Ozols RF; Behrens BC; Ostchega Y; Young RC
Cancer Treat Rev; 1985 Sep; 12 Suppl A():59-65. PubMed ID: 3910223
[TBL] [Abstract][Full Text] [Related]
8. High-dose carboplatin in refractory ovarian cancer patients.
Ozols RF; Ostchega Y; Curt G; Young RC
J Clin Oncol; 1987 Feb; 5(2):197-201. PubMed ID: 3543243
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma.
Piccart MJ; Nogaret JM; Marcelis L; Longrée H; Ries F; Kains JP; Gobert P; Domange AM; Sculier JP; Gompel C
J Natl Cancer Inst; 1990 Apr; 82(8):703-7. PubMed ID: 2181152
[TBL] [Abstract][Full Text] [Related]
10. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.
Lund B; Hansen M; Hansen OP; Hansen HH
J Clin Oncol; 1989 Oct; 7(10):1469-73. PubMed ID: 2674334
[TBL] [Abstract][Full Text] [Related]
11. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of adjuvant carboplatin-epirubicin chemotherapy in advanced ovarian cancer after radical surgery.
Pickel H; Petru E; Lahousen M; Stettner H; Lehnert M
Oncology; 1989; 46(4):222-5. PubMed ID: 2662087
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of the renal function in patients with ovarian carcinoma subjected to polychemotherapy including cisplatin or carboplatin].
Gadducci A; Facchini V; Dell'Arciprete T; Del Bravo B; Galigani P; Palla R; Fioretti P
Minerva Ginecol; 1988 Jan; 40(1):33-8. PubMed ID: 3287233
[No Abstract] [Full Text] [Related]
14. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
[TBL] [Abstract][Full Text] [Related]
15. The role of platinum dose intensity in the management of ovarian cancer.
Markman M
J Cancer Res Clin Oncol; 1993; 119(9):511-2. PubMed ID: 8325902
[No Abstract] [Full Text] [Related]
16. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.
Colombo N; Speyer JL; Green M; Canetta R; Beller U; Wernz JC; Meyers M; Widman T; Blum RH; Piccart M
Cancer Chemother Pharmacol; 1989; 23(5):323-8. PubMed ID: 2650904
[TBL] [Abstract][Full Text] [Related]
17. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease.
Lund B; Hansen M; Hansen OP; Hansen HH
J Clin Oncol; 1990 Jul; 8(7):1226-30. PubMed ID: 2113570
[TBL] [Abstract][Full Text] [Related]
18. [Phase III study of carboplatin in ovarian cancer].
Kato T; Nishimura H; Yamabe T; Terashima Y; Kasamatsu T; Hirabayashi K; Nishiya I; Yajima A; Takamizawa H; Tsutsui F
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2297-304. PubMed ID: 3044276
[TBL] [Abstract][Full Text] [Related]
19. [Carboplatin/epirubicin/prednimustine (Sterecyt) as an adjuvant chemotherapy combination in ovarian cancer treated by radical surgery].
Pickel H
Gynakol Rundsch; 1989; 29 Suppl 2():357-8. PubMed ID: 2693256
[No Abstract] [Full Text] [Related]
20. Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.
Neijt JP; Engelholm SA; Witteveen PO; Tuxen MK; Sørensen PG; Hansen M; Hirsch F; Sessa C; de Swart C; van Houwelingen HC; Lund B; Hansen SW
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-36-S15-39. PubMed ID: 9346220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]